Nyxoah SA (NYXH): Price and Financial Metrics


Nyxoah SA (NYXH): $5.84

0.09 (+1.57%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

NYXH Stock Price Chart Interactive Chart >

Price chart for NYXH

NYXH Price/Volume Stats

Current price $5.84 52-week high $23.05
Prev. close $5.75 52-week low $5.36
Day low $5.77 Volume 4,700
Day high $5.90 Avg. volume 5,352
50-day MA $6.21 Dividend yield N/A
200-day MA $12.72 Market Cap 145.67M

Nyxoah SA (NYXH) Company Bio


Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.


NYXH Latest News Stream


Event/Time News Detail
Loading, please wait...

NYXH Latest Social Stream


Loading social stream, please wait...

View Full NYXH Social Stream

Latest NYXH News From Around the Web

Below are the latest news stories about NYXOAH SA that investors may wish to consider to help them evaluate NYXH as an investment opportunity.

Nyxoah to Participate in the Piper Sandler 34th Annual Healthcare Conference

Nyxoah to Participate in the Piper Sandler 34th Annual Healthcare Conference Mont-Saint-Guibert, Belgium – November 17, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Piper Sandler 34th Annual Healthcare Conference, which takes place November 2

Yahoo | November 17, 2022

Wall Street Analysts See a 240% Upside in Nyxoah SA (NYXH): Can the Stock Really Move This High?

The mean of analysts' price targets for Nyxoah SA (NYXH) points to a 240% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Yahoo | November 16, 2022

Nyxoah Reports Third Quarter 2022 Financial and Operating Results

REGULATED INFORMATION Nyxoah Reports Third Quarter 2022 Financial and Operating Results DREAM US pivotal 12-month clinical data expected in fall of 2023 Mont-Saint-Guibert, Belgium – November 8, 2022, 10:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today reported financial and operating results for the quar

Yahoo | November 8, 2022

Nyxoah Announces Change to Board of Directors

Nyxoah Announces Change to Board of Directors Mont-Saint-Guibert, Belgium – October 24, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Raymond Cohen resigned as member of the board of directors of the Company effective October 18, 2022. About NyxoahNyxoah is a medical technology

Yahoo | October 24, 2022

Nyxoah to Participate in the Jefferies London Healthcare Conference

Nyxoah to Participate in the Jefferies London Healthcare Conference Mont-Saint-Guibert, Belgium – October 20, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Jefferies London Healthcare Conference, which takes place November 15-17, 2022, at The

Yahoo | October 20, 2022

Read More 'NYXH' Stories Here

NYXH Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year -71.10%
3-year N/A
5-year N/A
YTD -74.61%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.627 seconds.